Travere Therapeutics Files 8-K on Financials
Ticker: TVTX · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1438533
| Field | Detail |
|---|---|
| Company | Travere Therapeutics, Inc. (TVTX) |
| Form Type | 8-K |
| Filed Date | Jan 13, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
Related Tickers: TVTX
TL;DR
Travere Therapeutics filed an 8-K on Jan 13, 2025, reporting on financials. No major news, just standard procedure.
AI Summary
On January 13, 2025, Travere Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as financial statements and exhibits. No specific financial figures or operational updates were detailed in the provided text, but the filing indicates a standard reporting event.
Why It Matters
This 8-K filing serves as an official notification of Travere Therapeutics' financial reporting status, providing transparency to investors about the company's operational and financial condition.
Risk Assessment
Risk Level: low — This filing is a routine 8-K report for financial condition and results of operations, with no immediate indication of significant positive or negative events.
Key Players & Entities
- Travere Therapeutics, Inc. (company) — Registrant
- Retrophin, Inc. (company) — Former Company Name
- Desert Gateway, Inc. (company) — Former Company Name
- January 13, 2025 (date) — Date of Report
FAQ
What is the primary purpose of this 8-K filing for Travere Therapeutics, Inc.?
The primary purpose of this 8-K filing is to report on Travere Therapeutics, Inc.'s Results of Operations and Financial Condition, as well as to provide Financial Statements and Exhibits.
On what date was this 8-K report filed?
This 8-K report was filed on January 13, 2025.
What was Travere Therapeutics, Inc.'s former company name?
Travere Therapeutics, Inc. was formerly known as Retrophin, Inc. and Desert Gateway, Inc.
Where is Travere Therapeutics, Inc. headquartered?
Travere Therapeutics, Inc. is headquartered at 3611 Valley Centre Drive, Suite 300, San Diego, CA 92130.
What is the Standard Industrial Classification code for Travere Therapeutics, Inc.?
The Standard Industrial Classification code for Travere Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 556 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2025-01-13 07:30:16
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share TVTX The Nasdaq Global Marke
Filing Documents
- tvtx-20250113.htm (8-K) — 33KB
- aex991_2024q4xearningsprex.htm (EX-99.1) — 47KB
- image.jpg (GRAPHIC) — 9KB
- 0001438533-25-000002.txt ( ) — 228KB
- tvtx-20250113.xsd (EX-101.SCH) — 2KB
- tvtx-20250113_lab.xml (EX-101.LAB) — 22KB
- tvtx-20250113_pre.xml (EX-101.PRE) — 13KB
- tvtx-20250113_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On January 13, 2025, Travere Therapeutics, Inc. (the "Company") issued a press release announcing certain preliminary financial results for the fourth quarter and year ended December 31, 2024. A copy of the press release is attached as Exhibit 99.1 to this current report. The information in this Item 2.02, and Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 2.02, and Exhibit 99.1 attached hereto, shall not be incorporated by reference into any registration statement or other document filed with the Securities and Exchange Commission, whether filed before or after the date hereof regardless of any general incorporation language in any such filing, unless the registrant expressly sets forth in such filing that such information is to be considered "filed" or incorporated by reference therein.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release of Travere Therapeutics, Inc. dated January 13, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TRAVERE THERAPEUTICS, INC. Dated: January 13, 2025 By: /s/ Eric Dube Name: Eric Dube Title: Chief Executive Officer